dapagliflozin
UkraineDrugs containing this active substance
-
The drug is prescribed for adults to treat inadequately controlled type 2 diabetes mellitus, symptomatic chronic heart failure, as well as chronic kidney disease. It may also be prescribed to children aged 10 years and older with type 2 diabetes mellitus.
Form: tablets, film-coated
Active substance Dosage dapagliflozin 5 mg ATC: A10BK01
Manufacturer: AstraZeneca AB (drug testing)
-
The drug is prescribed to adults for the treatment of type 2 diabetes mellitus (either as monotherapy or in combination with other agents), for the treatment of chronic kidney disease, and for the treatment of symptomatic chronic heart failure.
Form: tablets, film-coated
Active substance Dosage dapagliflozin 10 mg ATC: A10BK01
Manufacturer: AstraZeneca AB (drug testing)
-
The drug is intended for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. It is also used to reduce the risk of hospitalization due to heart failure in patients with established cardiovascular disease or risk factors.
Form: tablets, film-coated, prolonged release
Active substance Dosage dapagliflozin 10 mg metformin 1000 mg ATC: A10BD15
Manufacturer: AstraZeneca Pharmaceuticals LP (manufacturing of medicinal product, quality control testing, packaging and release)
-
The drug is intended for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. It also helps to reduce the risk of hospitalization due to heart failure in patients with type 2 diabetes and established cardiovascular disease or risk factors.
Form: tablets, film-coated, prolonged release
Active substance Dosage dapagliflozin 5 mg metformin 1000 mg ATC: A10BD15
Manufacturer: AstraZeneca Pharmaceuticals LP (manufacturing of medicinal product, quality control testing, packaging and release)
-
The drug is intended for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. It is also used to reduce the risk of hospitalization due to heart failure in patients with type 2 diabetes and established cardiovascular disease or risk factors.
Form: tablets, film-coated, prolonged release
Active substance Dosage dapagliflozin 10 mg metformin 500 mg ATC: A10BD15
Manufacturer: AstraZeneca Pharmaceuticals LP (manufacturing of medicinal product, quality control testing, packaging and release)